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The importance of circulating tumor 
products as `liquid biopsies` in colorectal 
cancer 
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Abstract Liquid biopsies represent an array of plasma analysis tests that are studied to 
evaluate and identify circulating tumor products, especially circulating tumor cells 
(CTCs) and circulating tumor DNA (ctDNA).  Examining such biomarkers in the 
plasma of colorectal cancer patients has attracted attention due to its clinical 
significance in the treatment of malignant diseases. Given that tissue samples are 
sometimes challenging to procure or unsatisfactory for genomic profiling from 
patients with colorectal cancer, trustworthy biomarkers are mandatory for guiding 
treatment, monitoring therapeutic response, and detecting recurrence.  
This review considers the relevance of flowing tumor products like circulating 
tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating messenger RNA 
(mRNA), circulating micro RNA (miRNA), circulating exosomes, and tumor 
educated platelets (TEPs) for patients with colorectal cancer. 
  
 
Keywords  liquid biopsies, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), colorectal 
cancer (CRC), circulating exosomes, tumor educated platelets (TEPs)   
Highlights ✓ Circulating tumor cells and circulating tumor DNA serve as a promising step forward 
in the detection and monitoring of colorectal cancer.   
✓ More extensive research is required to determine the extent to which liquid biopsies 
would be able to impact the patient diagnosis and therapy      
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Introduction 
Colorectal cancer represents one of the dominant 
causes of mortality globally, and through precision 
medicine it has become one of the most promising areas 
for cancer therapy (1).  Colorectal cancer appears in the 
colon or rectum, part of the large intestine. The 
preponderance of colorectal cancers are 
adenocarcinomas.  Most of these cancers develop as a 
result of aging and lifestyle, with only a negligible 
proportion determined by genetic factors (2). Included 
among the risk factors are sedentary lifestyle, smoking, 
and obesity. Dietary factors, inflammatory bowel 
disease, and several genetic disorders also play a 
significant part in the evolution of colorectal cancer (3). 
Bowel cancer can be diagnosed by medical imaging and 
biopsy, but these procedures usually detect tumors only 
in the latter stages of development (2, 3). 
In recent years, increasing attention has been given 
to liquid biopsy, centering mainly on the examination 
and determination of circulating tumor cells (CTC) and 
circulating cell-free tumor DNA (ctDNA) because of its 
relevance to precision medicine. The study of circulating 
tumor products has opened a new, important and precise 
pathway to diagnostic medicine. Traditional serum 
biomarkers are becoming inadequate for therapeutic 
guidance; because of its non-invasive nature and the 
amount of information obtained about the tumor, liquid 
biopsy has been increasingly considered for colorectal 
cancer diagnosis and therapeutic and recurrence 
monitoring (4).  
For patients with colorectal malignancies, it is 
always beneficial to diagnose and genotype tumors using 
blood-based biopsies, but sometimes tumor tissue 
samples may be insufficient or difficult to procure due to 
the low quantity of tumor content and given the invasive 
nature for collecting samples. Liquid biopsies offer 
substantial information about inter- and intra-tumoral 
heterogeneity, in addition to revealing dominant 
mutation and relevant subclones of the tumor burden (5, 
6).  
This review evaluates the potential of this 
circulating tumor product to help identify new cancers, 
reveal recurrences, classify sensitivity, determine 
resistance, and predict prognosis. 
 
Discussion 
➢ Accepted detection methods of circulating 
tumor products 
• CTCs 
CTC presence was first confirmed 140 years ago (7). 
CTCs are rare, often as low as one cell in 10.000.000 
leukocytes in the blood of cancer patients, so detection 
technologies are adopted in conjunction with enrichment 
procedures. The exclusive medical device cleared by the 
Food and Drug Administration (FDA) for CTC 
enumeration and selection is the CellSearch System 
(Veridex, New Jersey, USA).  
To use this detection method effectively, CTCs must 
have the following properties: the staining pattern must 
be cytokeratin phycoerythrin and the fluorescent stain 
DAPI (4',6-diamidino-2-phenylindole) needs to be 
positive; also the leukocyte common antigen CD45 has 
to be negative, the shape of the cell has to be round with 
a minimum size of 4um, and lastly, the nucleus ought to 
be visible (8).  
This system also detects a specific protein called 
antibodies against epithelial cell-adhesion molecule 
(EpCAM). The EpCAM protein is found exclusively on 
the exterior surface of the circulating tumor cells. 
CellSearch System pulls the CTCs out, using a magnetic 
field, after the EpCam antibodies are previously attached 
to a magnetic bead (9). But even after taking such effects 
into consideration, CTCs are rarely used in CRC because 
of their low numbers (approximately 2 cells per 7,5ml of 
blood) (10) (Figure 1). 
 
Figure 1. The CellSearch technology 
• ctDNA 
In patients with CRC, ctDNA can be detected in 48–
73% of patients (11), and in the case of advanced 
metastatic gastrointestinal cancers, the detection rate 
increases to almost 100%, so for this reason ctDNA is 
more useful than CTCs. In order to detect ctDNA, a gene 
mutation has to exist in the tumor genome, with the 
genes most probably mutated being APC, TP53, and 
KRAS. In recent years many sensitive methods for 
detecting ctDNA have been developed, such as: 
BEAMing (12), Safe-SeqS, TamSeq (13), and digital 
PCR (14, 15).  
The BEAMing technique (beads, emulsify-cation, 
amplification and magnetics) is very precise, detecting 
PIK3CA mutation from the ctDNA in the peripheral 
blood (16). Over the past several years there has been an 
increesed need for oncological medication that focuses 
directly on mutated genes (17, 18). The first stage of the 
BEAMing technique purifies the ctDNA. In the second 
stage, the ctDNA is amplified with the help of the PCR 
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technique. In the third step, specific ctDNA sequences 
undergo an emulsion process, so that in the fourth and 
final stages the sequences attach themselves to magnetic 
microbeads and thus can be easily isolated (19, 20). 
In conclusion, the BEAMing technique is important 
because of its ability to isolate and quantify different 
gene mutations, even when in very low quantity. 
• mRNAs and miRNA 
Circulating messenger RNA and circulating micro 
RNA were first detected and analyzed in the late 1990s 
using the quantitative reverse transcriptase (qRT)-
PCR method. Later, mRNAs were identified in the 
peripheral blood of colorectal cancer patients (21, 22). 
Some methods determine hTERT mRNA as a marker for 
colorectal cancer through telomerase activity since it is 
generally suppressed in healthy tissues. miRNAs are 
stable in blood and plasma and can be measured using 
the qRT-PCR method, followed by the TaqMan PCR 
method. The TaqMan technique, initially developed in 
1991 by Cetus Corporation, is constructed in such a way 
that, using a fluorogenic probe, it can isolate a specific 
RNA gene sequence. TaqMan method is especially used 
to maximize the precision of the PCR technique (23, 24). 
• Exosomes  
Recently it had been discovered that circulating 
exosomes could be identified in the plasma of cancer 
patients. These exosomes transport genetic material that 
can be utilized to monitor the tumor. This type of micro 
and nano circulating tumor product is extremely 
important in the detection and monitoring of the early 
stages of cancer. Conventional techniques for isolation 
are ultracentrifugation and density gradient separation, 
but these methods are impractical and time consuming 
(25). In recent years, a number of scientific techniques 
have been perfected that can detect and isolate exosomes. 
Plasmonic exosome detection, also known as SPR 
(Surface Plasmon Resonance), is a highly sensitive 
method able to detect as low as 1 molecule. 
Weissleder/Lee group established a sensor named 
nPLEX (nano plasmonic exosome) that has multiple 
nanohole arrays that are able to detect all types of 
exosomes (26, 27). 
• TEPs (Tumor Educated Platelets) 
Tumor educated platelets (TEPs) are the result of the 
synergy between tumor cells and blood platelets. TEPs 
play an important role in tumor proliferation by 
modifying the RNA genetic profile. Of all liquid 
biopsies, TEPs are probably the most important in 
detection. Best et al. (2015) initially discovered their 
value in diagnostic oncology. Their research used the 
peripheral blood of 283 patients, of whom 228 were later 
diagnosed with cancer and 55 were healthy individuals. 
The study correctly diagnosed the cancer patients using 
TEPs in 96% of cases, demonstrating that TEPs modify 
mainly according to the type of cancer and in a very low 
percentage by the gravity of the disease or metastases. In 
summary, the power of TEPs to positively show the 
location of the tumor could potentially advance the usage 
of liquid biopsies in diagnostic oncology (28, 29). 
➢ Biomarkers role in the screening of patients with 
CRC 
Current screening methods include imaging, blood 
protein tests, histologic diagnostic, and direct 
visualization, but many of these tests cause discomfort 
(colonoscopies) or are unpleasant (stool studies) for the 
patient, and they may expose the patient to radiation (CT 
scans). Liquid biopsy is a non-invasive procedure having 
minimal risk for the patient. Furthermore, liquid biopsy 
offers the potential for studying the genomic evolution of 
the disease. In 2014, the US Food and Drug 
Administration approved the Cologuard test which 
detects abnormal fecal DNA and fecal hemoglobin (30). 
This test assesses DNA alterations which are distinct for 
the primary tumor, including abnormal methylated Bone 
morphogenetic protein 3, also known as osteogenin, the 
NDRG4 gene that is an alteration of the KRAS gene, the 
human beta-actin gene, and hemoglobin metalloprotein. 
In 2016, the FDA approved Epi proColon (Epigenomics, 
Berlin, Germany), a test that detects and examines the 
differential blood biomarker, methylated Septin 9 DNA. 
This marker is methylated in colorectal cancer. This test 
is possible with the use of the Real-Time PCR method. 
In 2014, Perrone et al. (31) directed a study in a high-risk 
population for colorectal cancer assessing circulating 
tumor DNA adopting the PCR method. The research 
revealed that ctDNA was prognosticative for colorectal 
cancer; however, it was not predictive for premalignant 
lesions, indicating that ctDNA represents an important 
complementary screening method in addition to 
traditional explorations (32, 33). 
➢ Pronostic value 
In colorectal cancer there is demand for 
supplementary prognostic markers to improve the 
managment of affected patients. Because circulating 
tumor products like CTCs and ctDNA are directly 
associated with the tumor burden, they can represent 
valuable independent prognostic biomarkers (Figure 2). 
Both CTCs and ctDNA are shown to correspond with 
survival in the case of colorectal cancer patients. A 
recent study supervised by Spindler et al. that included 
229 patients with chemotherapy refractory mCRC and 
100 healthy individuals showed that patients with low 
concentrations of ctDNA had a signifficantly higher rate 
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of survival than those with higher levels of ctDNA (19). 
However, in a study directed by Cohen et al. in 2009, 
430 patients with metastatic colorectal cancer were 
divided into 2 separate groups based on the levels of 
CTCs, those that had <3CTCs per 7,5ml of plasma, and 
those that had >3CTCs per 7,5ml of plasma. Their results 
showed that patients having lower quantities of CTCs 
have almost twice the survival rate of those with higher 
quantities of CTCs (34). The amount of CTCs in the 
plasma of patients diagnosed with colorectal cancer is 
lower than in other types of cancer. A study by Deneve 
et al. on 75 patients diagnosed with CRC in situ and 
metastatic colorectal cancer, that studied the count of 
CTCs in both peripheral and mesenteric blood, showed a 
significant discrepancy between the two, therefore 
supporting the idea that the liver acts as a filter for CTCs 
in colorectal cancer (35).  
 
Figure 2. Clinical value of circulating tumor cells 
and circulating tumor DNA for cancer patients. 
➢ Detection of resistance to therapies    
The objective of personalized cancer therapy is to 
uncover a cancer’s particular genes and proteins that 
permit the cancer cells to multiply, expand, and 
withstand aggressive therapy (36). KRAS and NRAS 
gene alterations are currently accepted as biomarkers that 
foretell resistance to anti-epidermal growth factor 
receptor (anti-EGFR) (37) (Figure 3). In a recent study 
organized by Spindler et al. (38) that included 105 
patients previously diagnosed with methastatic colorectal 
cancer (mCRC) indicated that KRAS mutations occured 
in 38% of patients that initially reacted to anti-EGFR 
treatment therapy medication.  
The patients were prescribed irinotecan 350 mg/m2 
q3w and weekly cetuximab (250 mg/m2) and continued 
with the treatment until improvement or improper 
toxicity. Then ctDNA and mutated KRAS alleles were 
analyzed. The study tesified to the development of 
KRAS mutations in the plasma during treatment even 
before radiological indication of progression. More 
recent applications have now accepted the ctDNA system 
of attained resistance in the evolution of KRAS 
mutations (39, 40). 
 
Figure 3. EGFR signaling in both Wild Type KRAS 
and Mutated KRAS. 
 
Conclusions 
Given that cancers are associated with mutated 
genes, it is only normal that genetic analysis should be 
included in recent years for the diagnosis, prognosis, and 
treatment of patients. Tumors discharge CTCs in the 
peripheral blood and these cells release circulating tumor 
DNA; thus, researchers have developed a number of 
detection technologies for the analysis of such mutations. 
More extensive research is required to determine the 
extent to which liquid biopsies impact patient care, but 
we can now conclude that circulating tumor cells (CTC) 
and circulating tumor DNA (ctDNA) serve as a 
promising step forward in the detection and monitoring 
of colorectal cancer.   
The power of liquid biopsies from the peripheral 
blood to diagnose and monitor cancers could eventually 
simplify the management of oncological diseases, lower 
costs by focusing treatment, and eliminate unpleasant 
diagnostic tests for patients. 
Liquid biopsy has the capacity to manage the 
complete array of colorectal cancer diseases. The study 
of circulating tumor material in the plasma has 
demonstrated the ability to diagnose the disease from 
early stages of development and, more importantly, to 
enable oncology caretakers the possibility of highly 
targeted drug therapy. Studying circulating tumor 
products gives researchers a chance to better understand 
the process of recurrence and metastasation in colorectal 
cancer.  
In conclusion, the understanding of circulating 
tumor products is likely to transform the way clinicians 
approach colorectal cancer disease in the near future. 
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